Redeye comments on Xbrane following yesterday’s press release, which provided updates on a conditional financing solution and the FDA re-inspections of the company’s contract manufacturing facilities. Xbrane is approaching its BsUFA date next week, with the potential for a US approval of its ranibizumab biosimilar.
LÄS MER
